Status:
UNKNOWN
A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
Lead Sponsor:
University of Glasgow
Collaborating Sponsors:
NHS Greater Glasgow and Clyde
Glasgow Western Infirmary
Conditions:
Basal Cell Carcinoma
Eligibility:
All Genders
49-89 years
Phase:
NA
Brief Summary
The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cre...
Detailed Description
Basal Cell Carcinomas (BCC) are the commonest form of skin cancer in the white population. The face is where they most frequently occur and the nodular BCCs are the commonest type. Curettage and caute...
Eligibility Criteria
Inclusion
- Well-defined primary, not previously treated nodulo-cystic BCC
- Size of the lesions: ≤ 1cm diameter
- Facial lesions
- Patient compliance competent
- Patient physically able to apply the treatment (cream)
Exclusion
- Recurrent lesions
- Superficial, morphoeic or pigmented BCC
- Lesions close to vital structures; i.e. where C\&C is not considered a standard treatment (eyelids, inner canthus, free borders)
- Lesions within 1 cm of the eyelids, nose, lips and hairline
- Immunosuppressed patients
- Women in childbearing age, pregnancy and breast-feeding
- Ages \<50 or \>90
- Patients compliance incompetent
- Patients physically incapable to apply the treatment (cream)
- Patients with Gorlin Syndrome (nevoid Basal Cell Carcinoma syndrome)
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00463359
Last Update
April 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermatology Department, Western Infirmary
Glasgow, Lanarkshire, United Kingdom, G11 6NT